• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Jun 25. 2020
Basilea announces partial repurchase offer for at least CHF 90 million and up to CHF 110 million in principal amount of its outstanding convertible bonds due 2022
Read more Download
Jun 24. 2020
Basilea successfully places CHF 125 million senior convertible bonds
Read more Download
Jun 24. 2020
Basilea launches the placement of CHF 100 million senior convertible bonds with an increase option of CHF 25 million
Read more Download
Jun 23. 2020
Basilea enters into sale and leaseback agreement for corporate headquarters building
Read more
Download
Jun 22. 2020
Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cresemba® in Russia
Read more
Download
May 28. 2020
Basilea provides corporate update
Read more
Download
Apr 29. 2020
Basilea announces appointment of new Head of Global Quality Management
Read more
Download
Apr 08. 2020
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
Read more
Download
Feb 27. 2020
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific
Read more
Download
Feb 18. 2020
Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019
Read more
Download
  • previous
  • 1
  • …
  • 14
  • 15
  • 16
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil